Data from the TRISCEND II trial suggest that hospital cost and length of stay for patients undergoing TTVR vary by complication, with new pacemaker or cardiac implantable electronic device (CIED) implantation and renal replacement therapy as the primary drivers. www.tctmd.com/news/triscen...
New pacemaker/CIED implants and need for renal replacement therapy were the biggest contributors.
